CaBP2 Inhibitors

Chemical inhibitors of CaBP2 exert their inhibitory action by impeding the protein's ability to bind calcium, which is essential for its function. The selected chemicals, all calcium channel blockers, operate by reducing the intracellular concentration of calcium ions. For instance, Verapamil and Nifedipine directly block voltage-gated L-type calcium channels, leading to a reduction in the influx of calcium ions. Without sufficient calcium, CaBP2 cannot perform its calcium-dependent regulatory roles within the cell. Similarly, Amlodipine and Diltiazem lower calcium ion availability by inhibiting the influx through the same type of channels. By reducing the internal pool of calcium, these chemicals ensure that CaBP2 is unable to interact with its typical calcium ion partners, consequently inhibiting the protein's activity.

Furthermore, other chemicals like Felodipine and Isradipine also decrease calcium levels in the cellular environment by targeting and blocking L-type calcium channels. Nicardipine, Nimodipine, and Nitrendipine share a similar mechanism, selectively inhibiting calcium channels and thus, diminishing the calcium ion concentration that is crucial for the functional activity of CaBP2. Lacidipine, Lercanidipine, and Manidipine complete the list of selected inhibitors, each contributing to the reduction of intracellular calcium, and by extension, CaBP2 activity. Each of these chemicals, by lowering the availability of calcium ions needed for the proper functioning of CaBP2, effectively inhibits the protein. This inhibition is a direct consequence of the calcium channel blockade, which is the primary mode of action of these selected compounds.